| Code | Description | Claims | Beneficiaries | Total Paid |
| J9271 |
Injection, pembrolizumab, 1 mg |
9,622 |
3,285 |
$20.37M |
| J9299 |
Injection, nivolumab, 1 mg |
3,965 |
1,106 |
$7.23M |
| J1561 |
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg |
9,071 |
1,900 |
$6.79M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
162,270 |
113,863 |
$6.70M |
| J9035 |
Injection, bevacizumab, 10 mg |
4,514 |
2,554 |
$5.37M |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
2,247 |
1,736 |
$4.57M |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
3,345 |
3,246 |
$4.37M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
20,789 |
19,548 |
$3.84M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
8,323 |
7,731 |
$2.95M |
| 77386 |
|
13,708 |
1,268 |
$2.77M |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
19,891 |
17,917 |
$2.34M |
| A0429 |
Ambulance service, basic life support, emergency transport (bls-emergency) |
53,752 |
32,391 |
$2.22M |
| 0760 |
|
168,916 |
127,575 |
$2.12M |
| J0897 |
Injection, denosumab, 1 mg |
4,346 |
2,928 |
$2.11M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
34,962 |
19,756 |
$1.97M |
| J9306 |
Injection, pertuzumab, 1 mg |
3,056 |
433 |
$1.88M |
| J9312 |
Injection, rituximab, 10 mg |
1,467 |
519 |
$1.85M |
| J2505 |
Injection, pegfilgrastim, 6 mg |
1,578 |
1,079 |
$1.82M |
| 0450 |
Emergency room services |
99,173 |
86,430 |
$1.80M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
33,087 |
26,759 |
$1.78M |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
7,884 |
7,369 |
$1.39M |
| Q5108 |
Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg |
1,868 |
1,289 |
$1.34M |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
5,980 |
5,783 |
$1.26M |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
8,540 |
8,038 |
$1.22M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
39,188 |
26,562 |
$1.19M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
18,916 |
12,708 |
$1.14M |
| 80053 |
Comprehensive metabolic panel |
164,182 |
116,872 |
$1.12M |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
5,320 |
2,209 |
$1.12M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
7,776 |
7,521 |
$1.12M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,673 |
6,152 |
$1.07M |
| Q5118 |
Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg |
1,441 |
524 |
$1.00M |
| G0378 |
Hospital observation service, per hour |
3,680 |
3,440 |
$985K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
3,450 |
3,361 |
$828K |
| J0178 |
Injection, aflibercept, 1 mg |
1,572 |
1,393 |
$798K |
| J3490 |
Unclassified drugs |
184,272 |
69,799 |
$787K |
| Q5117 |
Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg |
877 |
541 |
$770K |
| 70450 |
Computed tomography, head or brain; without contrast material |
14,827 |
13,746 |
$756K |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
784 |
355 |
$753K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
156,154 |
109,869 |
$734K |
| 93975 |
|
3,744 |
3,502 |
$701K |
| 77301 |
|
868 |
807 |
$688K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
7,459 |
7,269 |
$686K |
| J9310 |
Injection, rituximab, 100 mg |
396 |
186 |
$662K |
| J9202 |
Goserelin acetate implant, per 3.6 mg |
1,749 |
1,523 |
$645K |
| 70498 |
|
4,576 |
4,389 |
$630K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
10,783 |
9,504 |
$625K |
| P9021 |
Red blood cells, each unit |
4,770 |
2,871 |
$616K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
46,661 |
39,964 |
$609K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
14,845 |
12,844 |
$589K |
| 96367 |
|
18,066 |
9,362 |
$562K |
| 96415 |
|
13,331 |
7,839 |
$548K |
| 0250 |
|
37,832 |
25,427 |
$547K |
| J0490 |
Injection, belimumab, 10 mg |
479 |
207 |
$541K |
| Q5123 |
Injection, rituximab-arrx, biosimilar, (riabni), 10 mg |
790 |
316 |
$531K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
30,423 |
22,868 |
$524K |
| 77014 |
|
8,721 |
927 |
$517K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
5,577 |
5,046 |
$511K |
| Q3014 |
Telehealth originating site facility fee |
40,279 |
33,983 |
$505K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
5,457 |
5,117 |
$478K |
| Q5107 |
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
473 |
173 |
$475K |
| 88185 |
|
2,738 |
1,212 |
$472K |
| 99199 |
Unlisted special service, procedure or report |
11,486 |
9,571 |
$466K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
11,702 |
10,964 |
$464K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
4,730 |
4,449 |
$462K |
| 43259 |
|
1,532 |
1,446 |
$455K |
| 0682 |
|
530 |
525 |
$449K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
9,492 |
4,077 |
$440K |
| 96417 |
|
10,445 |
6,204 |
$415K |
| P9034 |
Platelets, pheresis, each unit |
1,136 |
329 |
$412K |
| 36430 |
|
6,814 |
2,915 |
$408K |
| 93308 |
|
5,834 |
5,530 |
$399K |
| J0185 |
Injection, aprepitant, 1 mg |
5,449 |
1,674 |
$374K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
2,556 |
2,467 |
$370K |
| 71046 |
Radiologic examination, chest; 2 views |
19,277 |
17,686 |
$366K |
| P9073 |
Platelets, pheresis, pathogen-reduced, each unit |
706 |
203 |
$361K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
1,609 |
1,511 |
$361K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
6,681 |
6,130 |
$347K |
| J3380 |
Injection, vedolizumab, intravenous, 1 mg |
278 |
86 |
$346K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
11,733 |
10,416 |
$345K |
| J9395 |
Injection, fulvestrant, 25 mg |
938 |
777 |
$340K |
| 93970 |
|
2,424 |
2,276 |
$331K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
11,139 |
6,443 |
$330K |
| 70496 |
|
2,252 |
2,152 |
$329K |
| 74183 |
|
1,788 |
1,744 |
$329K |
| J0485 |
Injection, belatacept, 1 mg |
982 |
346 |
$320K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
12,125 |
6,586 |
$319K |
| 87497 |
|
8,538 |
5,276 |
$317K |
| 0121 |
|
100 |
98 |
$304K |
| 93971 |
|
3,589 |
3,295 |
$303K |
| 72197 |
|
1,268 |
1,234 |
$303K |
| 83735 |
|
66,193 |
39,326 |
$301K |
| 71045 |
Radiologic examination, chest; single view |
25,025 |
22,375 |
$294K |
| 77334 |
|
2,020 |
1,550 |
$294K |
| Z7502 |
|
7,671 |
7,596 |
$292K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
8,084 |
4,604 |
$286K |
| 0214 |
|
94 |
90 |
$284K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
9,012 |
7,908 |
$277K |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
1,164 |
1,126 |
$274K |
| 84443 |
Thyroid stimulating hormone (TSH) |
26,661 |
23,720 |
$268K |
| 59025 |
Fetal non-stress test |
8,814 |
5,019 |
$267K |
| 67028 |
Intravitreal injection of a pharmacologic agent |
6,685 |
5,613 |
$267K |
| 77412 |
|
4,884 |
657 |
$253K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
9,201 |
8,649 |
$248K |
| 83880 |
|
12,178 |
10,770 |
$248K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
9,202 |
8,648 |
$247K |
| 88341 |
|
3,435 |
3,136 |
$239K |
| 77336 |
|
5,173 |
2,203 |
$237K |
| 80197 |
|
19,937 |
10,735 |
$233K |
| 74178 |
|
1,565 |
1,535 |
$226K |
| L0172 |
Cervical, collar, semi-rigid thermoplastic foam, two-piece, prefabricated, off-the-shelf |
2,010 |
1,919 |
$224K |
| 71250 |
|
3,472 |
3,388 |
$216K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
1,087 |
1,018 |
$209K |
| 96416 |
|
3,267 |
1,678 |
$208K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
11,360 |
10,840 |
$204K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
11,117 |
10,112 |
$201K |
| 84484 |
|
27,486 |
21,539 |
$200K |
| 76604 |
|
6,033 |
5,634 |
$197K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
1,904 |
1,815 |
$192K |
| 0270 |
|
87,569 |
60,476 |
$192K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
34,283 |
29,391 |
$190K |
| Q5111 |
Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg |
152 |
80 |
$190K |
| 76830 |
Ultrasound, transvaginal |
3,390 |
3,195 |
$187K |
| 31237 |
|
859 |
734 |
$185K |
| 81001 |
|
79,528 |
64,562 |
$180K |
| 85027 |
|
36,527 |
27,092 |
$177K |
| 77338 |
|
912 |
799 |
$177K |
| 87631 |
|
3,774 |
3,249 |
$175K |
| 0352 |
|
594 |
448 |
$172K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
25,934 |
24,882 |
$172K |
| 87799 |
|
6,347 |
4,779 |
$169K |
| 80061 |
Lipid panel |
18,143 |
17,479 |
$169K |
| 84100 |
|
52,474 |
31,857 |
$168K |
| 70486 |
|
1,862 |
1,780 |
$168K |
| J9305 |
Injection, pemetrexed, not otherwise specified, 10 mg |
189 |
64 |
$163K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
3,835 |
2,879 |
$163K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
9,206 |
8,794 |
$162K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
26,762 |
8,524 |
$156K |
| 70491 |
|
1,328 |
1,283 |
$149K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
1,047 |
998 |
$149K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
25,116 |
14,378 |
$143K |
| 99231 |
Subsequent hospital care, per day, straightforward or low complexity |
1,936 |
1,721 |
$140K |
| J9228 |
Injection, ipilimumab, 1 mg |
30 |
14 |
$139K |
| 0300 |
|
13,448 |
2,707 |
$135K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
1,131 |
908 |
$132K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
25,046 |
21,189 |
$131K |
| 91010 |
|
388 |
384 |
$130K |
| 74174 |
|
612 |
592 |
$129K |
| 83690 |
|
28,271 |
24,911 |
$126K |
| 87536 |
|
2,136 |
1,945 |
$124K |
| 97597 |
|
2,692 |
1,747 |
$124K |
| Z9725 |
|
2,828 |
2,811 |
$121K |
| 86923 |
|
5,978 |
3,729 |
$121K |
| 83605 |
|
17,028 |
14,332 |
$120K |
| 85730 |
|
32,147 |
28,691 |
$117K |
| 83970 |
|
4,232 |
3,977 |
$115K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
2,193 |
1,969 |
$114K |
| J2704 |
Injection, propofol, 10 mg |
31,940 |
19,644 |
$113K |
| C1769 |
Guide wire |
3,713 |
3,307 |
$113K |
| 93017 |
|
3,089 |
2,928 |
$111K |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
425 |
389 |
$108K |
| C8928 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report |
464 |
462 |
$105K |
| 0510 |
|
64,209 |
48,916 |
$104K |
| 85610 |
|
43,893 |
35,223 |
$101K |
| 95708 |
|
371 |
369 |
$100K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
33,072 |
21,399 |
$98K |
| 77300 |
|
926 |
777 |
$97K |
| J2785 |
Injection, regadenoson, 0.1 mg |
1,301 |
1,219 |
$95K |
| 97750 |
|
3,345 |
1,767 |
$93K |
| 77290 |
|
719 |
635 |
$93K |
| 76770 |
|
2,369 |
2,259 |
$92K |
| C1760 |
Closure device, vascular (implantable/insertable) |
784 |
689 |
$91K |
| J9070 |
Cyclophosphamide, 100 mg |
622 |
282 |
$91K |
| 93325 |
|
1,698 |
1,625 |
$90K |
| 52000 |
|
1,645 |
1,584 |
$89K |
| 72131 |
|
1,556 |
1,455 |
$87K |
| 73610 |
|
5,514 |
4,967 |
$87K |
| 70543 |
|
470 |
450 |
$87K |
| 0360 |
|
25,163 |
10,678 |
$86K |
| 88307 |
|
1,178 |
1,098 |
$86K |
| 73562 |
|
5,820 |
5,218 |
$84K |
| 52310 |
|
316 |
312 |
$83K |
| J2777 |
Injection, faricimab-svoa, 0.1 mg |
87 |
65 |
$82K |
| 73130 |
|
4,998 |
4,438 |
$81K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
2,480 |
2,423 |
$81K |
| 82378 |
|
7,531 |
5,365 |
$80K |
| J9267 |
Injection, paclitaxel, 1 mg |
8,810 |
1,874 |
$80K |
| 73630 |
|
5,312 |
4,807 |
$79K |
| 0160 |
|
6,768 |
6,242 |
$79K |
| 86803 |
|
7,247 |
6,933 |
$79K |
| 59841 |
|
51 |
39 |
$78K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
996 |
987 |
$78K |
| V2632 |
Posterior chamber intraocular lens |
1,371 |
1,118 |
$78K |
| 86480 |
|
2,369 |
2,287 |
$78K |
| 72157 |
|
492 |
462 |
$77K |
| 86900 |
|
19,047 |
15,055 |
$76K |
| 88342 |
|
4,712 |
4,320 |
$76K |
| 88184 |
|
1,712 |
1,259 |
$75K |
| 77080 |
|
1,138 |
1,124 |
$75K |
| J2353 |
Injection, octreotide, depot form for intramuscular injection, 1 mg |
59 |
56 |
$75K |
| 36591 |
|
17,351 |
7,546 |
$75K |
| 82570 |
|
18,991 |
14,863 |
$74K |
| 73030 |
|
5,121 |
4,643 |
$74K |
| 86360 |
|
2,149 |
2,009 |
$73K |
| 87077 |
|
13,769 |
10,679 |
$73K |
| 83615 |
|
17,817 |
7,954 |
$73K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
4,159 |
1,548 |
$71K |
| 72156 |
|
405 |
390 |
$70K |
| 20610 |
|
2,445 |
2,212 |
$70K |
| 77295 |
|
284 |
181 |
$69K |
| 31231 |
|
2,077 |
2,013 |
$69K |
| 0710 |
|
24,778 |
22,030 |
$68K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
2,575 |
2,360 |
$67K |
| 90715 |
|
2,649 |
2,454 |
$65K |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
1,610 |
1,441 |
$65K |
| 72158 |
|
523 |
511 |
$65K |
| 73110 |
|
4,152 |
3,615 |
$65K |
| 49083 |
|
1,089 |
514 |
$64K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
13,388 |
11,972 |
$64K |
| 84439 |
|
11,593 |
10,378 |
$63K |
| J7518 |
Mycophenolic acid, oral, 180 mg |
1,144 |
986 |
$63K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
33,194 |
22,141 |
$63K |
| J2997 |
Injection, alteplase recombinant, 1 mg |
1,051 |
821 |
$63K |
| 86780 |
|
6,379 |
6,018 |
$63K |
| 31575 |
|
2,638 |
2,459 |
$63K |
| 82947 |
|
21,966 |
19,345 |
$62K |
| 95700 |
|
391 |
386 |
$62K |
| 84702 |
|
17,440 |
15,421 |
$61K |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
456 |
414 |
$59K |
| 86359 |
|
2,161 |
2,019 |
$59K |
| 36415 |
Collection of venous blood by venipuncture |
34,882 |
27,154 |
$59K |
| J1756 |
Injection, iron sucrose, 1 mg |
5,102 |
906 |
$59K |
| 36561 |
|
138 |
125 |
$58K |
| 76981 |
|
1,010 |
991 |
$57K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
18,495 |
9,918 |
$57K |
| 72128 |
|
919 |
850 |
$56K |
| 97165 |
|
2,179 |
1,468 |
$56K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
34,392 |
13,437 |
$55K |
| 76641 |
|
836 |
735 |
$55K |
| 76536 |
|
1,722 |
1,662 |
$55K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
7,031 |
4,539 |
$54K |
| 96402 |
|
4,127 |
3,626 |
$54K |
| 73590 |
|
3,884 |
3,512 |
$53K |
| J9045 |
Injection, carboplatin, 50 mg |
3,501 |
2,006 |
$52K |
| 96411 |
|
2,154 |
1,303 |
$52K |
| 73502 |
|
2,959 |
2,757 |
$52K |
| 96523 |
|
7,565 |
4,591 |
$51K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
696 |
672 |
$51K |
| 73552 |
|
2,995 |
2,752 |
$50K |
| 84466 |
|
6,293 |
5,812 |
$50K |
| J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
762 |
439 |
$50K |
| J7050 |
Infusion, normal saline solution, 250 cc |
23,098 |
10,433 |
$50K |
| Z7500 |
|
1,455 |
1,259 |
$49K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
2,070 |
1,858 |
$48K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
9,374 |
3,973 |
$48K |
| 82728 |
|
8,423 |
7,581 |
$48K |
| 86850 |
|
17,644 |
13,803 |
$47K |
| 0011A |
|
1,246 |
1,245 |
$47K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,477 |
2,120 |
$47K |
| 72100 |
|
3,317 |
3,110 |
$46K |
| C1729 |
Catheter, drainage |
3,655 |
2,910 |
$46K |
| 92504 |
|
5,351 |
5,092 |
$45K |
| 93880 |
|
563 |
539 |
$45K |
| 77066 |
Tomosynthesis, mammo |
568 |
563 |
$45K |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
1,133 |
1,030 |
$44K |
| 94060 |
|
956 |
946 |
$44K |
| 92134 |
|
11,419 |
10,721 |
$44K |
| 31579 |
|
728 |
716 |
$43K |
| 73080 |
|
2,673 |
2,464 |
$43K |
| 93798 |
|
1,867 |
290 |
$43K |
| 74018 |
|
2,384 |
2,119 |
$43K |
| P9035 |
Platelets, pheresis, leukocytes reduced, each unit |
91 |
37 |
$42K |
| 93356 |
|
1,538 |
1,506 |
$42K |
| 0012A |
|
1,067 |
1,066 |
$41K |
| 96376 |
|
1,593 |
1,399 |
$41K |
| 86901 |
|
19,006 |
15,019 |
$41K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
111 |
96 |
$41K |
| 50435 |
|
215 |
154 |
$41K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,722 |
1,998 |
$40K |
| 87186 |
|
8,985 |
7,832 |
$39K |
| 0370 |
|
7,618 |
6,972 |
$39K |
| 0402 |
|
559 |
454 |
$38K |
| 87070 |
|
7,712 |
6,930 |
$38K |
| C1726 |
Catheter, balloon dilatation, non-vascular |
2,341 |
2,182 |
$38K |
| 43235 |
|
212 |
193 |
$37K |
| 88142 |
|
4,173 |
4,077 |
$37K |
| 86140 |
|
10,650 |
9,851 |
$37K |
| 93296 |
|
2,088 |
2,046 |
$36K |
| 84156 |
|
12,965 |
9,374 |
$34K |
| C1788 |
Port, indwelling (implantable) |
499 |
474 |
$33K |
| 97010 |
|
3,813 |
828 |
$33K |
| 87040 |
|
3,974 |
3,169 |
$33K |
| 82043 |
|
7,968 |
7,582 |
$33K |
| C2617 |
Stent, non-coronary, temporary, without delivery system |
1,045 |
949 |
$33K |
| 76377 |
|
1,808 |
1,703 |
$33K |
| J9190 |
Injection, fluorouracil, 500 mg |
3,855 |
1,571 |
$32K |
| 87088 |
|
6,889 |
6,133 |
$32K |
| 36593 |
|
493 |
395 |
$32K |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
36 |
26 |
$32K |
| 38222 |
|
130 |
117 |
$32K |
| 77370 |
|
418 |
380 |
$31K |
| 87340 |
|
4,336 |
4,124 |
$31K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
5,548 |
5,001 |
$31K |
| 86160 |
|
1,904 |
1,669 |
$30K |
| 87081 |
|
8,463 |
7,750 |
$30K |
| 82803 |
|
3,312 |
2,944 |
$29K |
| 94729 |
|
1,482 |
1,453 |
$29K |
| 85379 |
|
4,235 |
3,850 |
$29K |
| 88313 |
|
932 |
854 |
$28K |
| 82610 |
|
2,451 |
2,140 |
$28K |
| J1453 |
Injection, fosaprepitant, 1 mg |
601 |
204 |
$28K |
| 31622 |
|
158 |
149 |
$28K |
| 73090 |
|
2,113 |
1,943 |
$28K |
| 83540 |
|
6,752 |
6,253 |
$28K |
| J1644 |
Injection, heparin sodium, per 1000 units |
8,265 |
4,781 |
$28K |
| 86301 |
|
2,420 |
1,702 |
$27K |
| 86255 |
|
2,666 |
2,454 |
$27K |
| 86235 |
|
661 |
603 |
$27K |
| 84550 |
|
8,957 |
3,922 |
$27K |
| 78306 |
|
258 |
239 |
$27K |
| 77065 |
Tomosynthesis, mammo |
431 |
405 |
$26K |
| Q5103 |
Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg |
27 |
25 |
$26K |
| 0320 |
|
730 |
548 |
$26K |
| 67228 |
|
343 |
295 |
$26K |
| 76776 |
|
301 |
284 |
$26K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
32,041 |
24,405 |
$25K |
| 72170 |
|
2,368 |
2,253 |
$25K |
| 72141 |
|
313 |
305 |
$25K |
| 0351 |
|
163 |
152 |
$25K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
29,849 |
24,973 |
$25K |
| 97162 |
|
1,778 |
1,731 |
$25K |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
3,180 |
2,900 |
$25K |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
3,748 |
623 |
$24K |
| 86304 |
|
2,871 |
2,186 |
$24K |
| 92521 |
|
418 |
380 |
$24K |
| 82105 |
|
1,982 |
1,775 |
$24K |
| 73564 |
|
2,052 |
1,866 |
$24K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
1,362 |
1,335 |
$24K |
| 87517 |
|
816 |
753 |
$24K |
| 84403 |
|
1,538 |
1,461 |
$24K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
478 |
473 |
$24K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
6,068 |
5,494 |
$23K |
| 93458 |
|
40 |
38 |
$23K |
| 93321 |
|
1,469 |
1,412 |
$23K |
| A9577 |
Injection, gadobenate dimeglumine (multihance), per ml |
804 |
773 |
$23K |
| 62323 |
|
184 |
181 |
$23K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
8,507 |
3,942 |
$23K |
| 82784 |
|
3,575 |
2,226 |
$23K |
| 76376 |
|
1,488 |
1,472 |
$23K |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
1,439 |
558 |
$23K |
| 81025 |
|
8,267 |
7,699 |
$22K |
| J9264 |
Injection, paclitaxel protein-bound particles, 1 mg |
45 |
14 |
$22K |
| 84153 |
|
1,876 |
1,684 |
$22K |
| 97602 |
|
853 |
567 |
$22K |
| 73060 |
|
1,714 |
1,561 |
$21K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
1,543 |
865 |
$21K |
| 85652 |
|
11,405 |
10,533 |
$21K |
| 76512 |
|
1,123 |
984 |
$21K |
| 86141 |
|
2,312 |
2,056 |
$21K |
| 76998 |
|
266 |
249 |
$21K |
| 86334 |
|
1,564 |
1,364 |
$20K |
| 87808 |
|
2,295 |
2,146 |
$20K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
10,911 |
7,927 |
$20K |
| 92202 |
|
2,187 |
2,104 |
$20K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
928 |
919 |
$20K |
| 85018 |
|
13,917 |
9,519 |
$19K |
| 69210 |
|
4,404 |
4,170 |
$19K |
| 83521 |
|
1,647 |
766 |
$19K |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
2,642 |
2,148 |
$19K |
| 90677 |
|
329 |
315 |
$19K |
| 73560 |
|
1,699 |
1,581 |
$18K |
| 72040 |
|
1,269 |
1,204 |
$18K |
| Q9968 |
Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg |
488 |
425 |
$18K |
| 90686 |
|
1,759 |
1,669 |
$18K |
| 82746 |
|
2,202 |
2,068 |
$18K |
| 87205 |
|
7,614 |
6,847 |
$18K |
| 0306 |
|
1,243 |
1,186 |
$18K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
9,520 |
7,799 |
$17K |
| 86704 |
|
2,042 |
1,940 |
$17K |
| 92083 |
|
3,245 |
3,158 |
$17K |
| 52356 |
|
30 |
28 |
$17K |
| 82330 |
|
2,510 |
2,267 |
$17K |
| J7507 |
Tacrolimus, immediate release, oral, 1 mg |
1,297 |
936 |
$17K |
| 87522 |
Neg quan hep c or qual rna |
534 |
507 |
$17K |
| 64615 |
|
735 |
707 |
$17K |
| J9206 |
Injection, irinotecan, 20 mg |
802 |
334 |
$16K |
| 97799 |
|
3,157 |
513 |
$16K |
| 76870 |
|
489 |
471 |
$16K |
| 86706 |
|
2,205 |
2,108 |
$16K |
| L0130 |
Cervical, flexible, thermoplastic collar, molded to patient |
290 |
278 |
$16K |
| 93923 |
|
201 |
199 |
$16K |
| 78816 |
|
12 |
12 |
$16K |
| 0324 |
|
585 |
550 |
$16K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
5,126 |
1,782 |
$16K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
555 |
525 |
$15K |
| 51798 |
|
2,207 |
2,099 |
$15K |
| J9060 |
Injection, cisplatin, powder or solution, 10 mg |
2,162 |
824 |
$15K |
| G0008 |
Administration of influenza virus vaccine |
2,630 |
2,593 |
$15K |
| 0002A |
|
400 |
400 |
$15K |
| P9047 |
Infusion, albumin (human), 25%, 50 ml |
229 |
123 |
$15K |
| 94726 |
|
397 |
389 |
$15K |
| 82274 |
|
1,207 |
1,175 |
$15K |
| 73700 |
|
206 |
197 |
$15K |
| 0001A |
|
406 |
406 |
$15K |
| 51700 |
|
804 |
739 |
$15K |
| J0612 |
Injection, calcium gluconate, not otherwise specified, 10 mg |
307 |
38 |
$14K |
| 80074 |
|
416 |
406 |
$14K |
| 10060 |
|
647 |
610 |
$14K |
| 82550 |
|
3,564 |
3,182 |
$14K |
| 77280 |
|
208 |
168 |
$14K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
22,238 |
20,088 |
$14K |
| 76937 |
|
1,185 |
1,037 |
$14K |
| 82010 |
|
2,455 |
2,160 |
$14K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
270 |
248 |
$14K |
| 76642 |
|
333 |
330 |
$14K |
| 92133 |
|
3,809 |
3,695 |
$14K |
| 76942 |
|
1,043 |
977 |
$14K |
| 93350 |
|
245 |
236 |
$14K |
| 0258 |
|
207 |
163 |
$13K |
| 96409 |
|
445 |
228 |
$13K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
17,166 |
14,412 |
$13K |
| 94762 |
|
1,279 |
1,188 |
$13K |
| 76000 |
|
757 |
644 |
$13K |
| 80076 |
|
2,846 |
2,609 |
$13K |
| 90632 |
|
235 |
215 |
$13K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
50 |
49 |
$13K |
| 86762 |
|
1,069 |
1,003 |
$12K |
| 97139 |
|
2,911 |
545 |
$12K |
| 82607 |
|
4,546 |
4,281 |
$12K |
| 97161 |
|
862 |
812 |
$12K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
8,505 |
6,880 |
$12K |
| 88112 |
|
524 |
511 |
$12K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
807 |
792 |
$12K |
| 43249 |
|
41 |
38 |
$12K |
| 86038 |
|
1,428 |
1,392 |
$12K |
| J3489 |
Injection, zoledronic acid, 1 mg |
688 |
655 |
$11K |
| 96401 |
|
1,660 |
700 |
$11K |
| 99499 |
|
192 |
152 |
$11K |
| 90662 |
|
2,019 |
1,987 |
$11K |
| 84165 |
|
1,836 |
1,610 |
$11K |
| 97166 |
|
740 |
726 |
$11K |
| 84402 |
|
647 |
622 |
$11K |
| 92523 |
|
152 |
147 |
$11K |
| 84270 |
|
782 |
739 |
$11K |
| 87102 |
|
2,396 |
2,146 |
$11K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
4,842 |
4,395 |
$11K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
2,421 |
1,444 |
$11K |
| 87184 |
|
2,678 |
2,384 |
$10K |
| 82533 |
|
964 |
785 |
$10K |
| 88173 |
|
486 |
444 |
$10K |
| 92136 |
|
1,279 |
1,257 |
$10K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
6,300 |
4,306 |
$10K |
| 20553 |
|
747 |
645 |
$10K |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
1,288 |
620 |
$10K |
| 90732 |
|
363 |
351 |
$10K |
| 83516 |
|
1,178 |
831 |
$10K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
2,441 |
1,540 |
$10K |
| C9463 |
Injection, aprepitant, 1 mg |
129 |
47 |
$10K |
| 84478 |
|
3,313 |
2,367 |
$10K |
| 0762 |
|
2,094 |
2,020 |
$10K |
| 0350 |
|
300 |
175 |
$10K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
7,017 |
6,157 |
$9K |
| 93925 |
|
102 |
102 |
$9K |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
2,561 |
2,380 |
$9K |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
6,382 |
5,423 |
$9K |
| 74230 |
|
186 |
183 |
$9K |
| C9257 |
Injection, bevacizumab, 0.25 mg |
1,398 |
1,240 |
$9K |
| 0301 |
|
449 |
392 |
$9K |
| 87206 |
|
2,836 |
2,328 |
$9K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
121 |
121 |
$9K |
| 0420 |
|
229 |
137 |
$9K |
| 82140 |
|
992 |
898 |
$8K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
13,057 |
8,950 |
$8K |
| C1751 |
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) |
402 |
360 |
$8K |
| 51702 |
|
920 |
791 |
$8K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
1,777 |
1,029 |
$8K |
| 91122 |
|
27 |
26 |
$8K |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
13 |
13 |
$8K |
| C1762 |
Connective tissue, human (includes fascia lata) |
12 |
12 |
$8K |
| 93990 |
|
114 |
103 |
$8K |
| Q5101 |
Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram |
467 |
54 |
$8K |
| 88312 |
|
471 |
443 |
$7K |
| 0730 |
|
147 |
141 |
$7K |
| 97802 |
|
83 |
83 |
$7K |
| 85384 |
|
1,262 |
841 |
$7K |
| 92250 |
|
1,211 |
1,160 |
$7K |
| 0761 |
|
1,080 |
751 |
$7K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
3,088 |
2,044 |
$7K |
| 96368 |
|
600 |
397 |
$7K |
| 99153 |
Mod sedat endo service >5yrs |
323 |
297 |
$7K |
| 80180 |
|
750 |
648 |
$7K |
| 88360 |
|
339 |
325 |
$7K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
301 |
281 |
$7K |
| 99152 |
|
860 |
807 |
$7K |
| 81003 |
|
4,153 |
3,420 |
$7K |
| 77001 |
|
182 |
166 |
$7K |
| 87075 |
|
1,555 |
1,399 |
$6K |
| 77470 |
|
168 |
143 |
$6K |
| 76380 |
|
74 |
41 |
$6K |
| 0430 |
|
144 |
81 |
$6K |
| 43242 |
|
27 |
24 |
$6K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,133 |
1,065 |
$6K |
| 92226 |
|
833 |
587 |
$6K |
| 0480 |
|
128 |
122 |
$6K |
| 0949 |
|
845 |
517 |
$6K |
| 90670 |
|
125 |
121 |
$6K |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
1,616 |
864 |
$6K |
| 86920 |
|
232 |
107 |
$6K |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
2,693 |
1,345 |
$6K |
| 16020 |
|
707 |
480 |
$6K |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
108 |
88 |
$5K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
44 |
44 |
$5K |
| 94010 |
|
330 |
316 |
$5K |
| 11730 |
|
1,305 |
1,251 |
$5K |
| 82248 |
|
1,493 |
1,241 |
$5K |
| 72190 |
|
274 |
259 |
$5K |
| 88304 |
|
766 |
740 |
$5K |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
736 |
341 |
$5K |
| 87015 |
|
1,646 |
1,252 |
$5K |
| A9576 |
Injection, gadoteridol, (prohance multipack), per ml |
732 |
702 |
$5K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
780 |
540 |
$5K |
| 86200 |
|
684 |
679 |
$5K |
| 92020 |
|
1,507 |
1,459 |
$5K |
| 84145 |
|
330 |
273 |
$5K |
| 0459 |
|
873 |
810 |
$5K |
| 93041 |
|
1,648 |
1,579 |
$4K |
| Q0511 |
Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period |
1,033 |
1,013 |
$4K |
| 64415 |
|
350 |
337 |
$4K |
| 82150 |
|
1,227 |
868 |
$4K |
| 73140 |
|
290 |
261 |
$4K |
| 82670 |
|
188 |
184 |
$4K |
| 74170 |
|
37 |
37 |
$4K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
4,065 |
3,471 |
$4K |
| J1815 |
Injection, insulin, per 5 units |
6,193 |
3,234 |
$4K |
| 86431 |
|
925 |
908 |
$4K |
| 97116 |
|
1,298 |
963 |
$4K |
| J3480 |
Injection, potassium chloride, per 2 meq |
2,098 |
1,363 |
$4K |
| 88237 |
|
171 |
162 |
$4K |
| 88177 |
|
221 |
201 |
$4K |
| J0456 |
Injection, azithromycin, 500 mg |
509 |
416 |
$4K |
| 87116 |
|
947 |
748 |
$4K |
| 92025 |
|
1,324 |
1,282 |
$4K |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
2,303 |
828 |
$4K |
| 86355 |
|
133 |
119 |
$4K |
| 36416 |
|
1,652 |
1,444 |
$4K |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
290 |
269 |
$4K |
| 96152 |
|
106 |
68 |
$4K |
| 88108 |
|
545 |
466 |
$4K |
| 86357 |
|
124 |
110 |
$4K |
| 78264 |
|
17 |
12 |
$4K |
| G0009 |
Administration of pneumococcal vaccine |
630 |
615 |
$4K |
| 0064A |
|
119 |
119 |
$3K |
| 87581 |
|
112 |
98 |
$3K |
| 66821 |
|
178 |
154 |
$3K |
| 83883 |
|
563 |
245 |
$3K |
| 87486 |
|
110 |
96 |
$3K |
| 86800 |
|
305 |
299 |
$3K |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
621 |
453 |
$3K |
| 84132 |
|
2,196 |
1,945 |
$3K |
| 76882 |
|
352 |
330 |
$3K |
| 86833 |
|
136 |
128 |
$3K |
| 86832 |
|
136 |
128 |
$3K |
| 76775 |
|
80 |
79 |
$3K |
| 71020 |
|
179 |
172 |
$3K |
| 87147 |
|
1,017 |
917 |
$3K |
| 62270 |
|
31 |
25 |
$3K |
| C1763 |
Connective tissue, non-human (includes synthetic) |
42 |
39 |
$3K |
| Q0512 |
Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period |
1,338 |
1,046 |
$3K |
| 77002 |
|
462 |
435 |
$3K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
1,060 |
914 |
$3K |
| 88300 |
|
841 |
788 |
$3K |
| 88172 |
|
325 |
297 |
$3K |
| 94761 |
|
208 |
199 |
$3K |
| 82977 |
|
559 |
538 |
$3K |
| 11732 |
|
994 |
961 |
$3K |
| 82565 |
|
1,545 |
1,430 |
$3K |
| 88309 |
|
38 |
37 |
$3K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,354 |
1,289 |
$3K |
| Z7610 |
|
440 |
402 |
$3K |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
3,143 |
2,579 |
$3K |
| J7312 |
Injection, dexamethasone, intravitreal implant, 0.1 mg |
16 |
13 |
$3K |
| 82950 |
|
664 |
649 |
$3K |
| 99234 |
|
3,715 |
2,976 |
$3K |
| 84295 |
|
1,736 |
1,540 |
$3K |
| 11056 |
|
1,155 |
1,099 |
$3K |
| 93922 |
|
70 |
66 |
$3K |
| 73200 |
|
27 |
26 |
$3K |
| 72110 |
|
164 |
161 |
$3K |
| 84146 |
|
262 |
247 |
$3K |
| 88264 |
|
103 |
96 |
$3K |
| A6197 |
Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing |
167 |
111 |
$2K |
| J0610 |
Injection, calcium gluconate (fresenius kabi), per 10 ml |
402 |
149 |
$2K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
62 |
52 |
$2K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
367 |
203 |
$2K |
| 88321 |
|
110 |
110 |
$2K |
| 0004A |
|
73 |
73 |
$2K |
| 88720 |
|
457 |
370 |
$2K |
| 87176 |
|
810 |
736 |
$2K |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
992 |
608 |
$2K |
| 72082 |
|
94 |
94 |
$2K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
98 |
88 |
$2K |
| 82365 |
|
317 |
300 |
$2K |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
301 |
128 |
$2K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
44 |
40 |
$2K |
| 93280 |
|
306 |
297 |
$2K |
| 93297 |
|
123 |
123 |
$2K |
| 74022 |
|
132 |
123 |
$2K |
| 73000 |
|
151 |
133 |
$2K |
| 64450 |
|
71 |
66 |
$2K |
| 83520 |
|
281 |
247 |
$2K |
| J2060 |
Injection, lorazepam, 2 mg |
3,322 |
2,375 |
$2K |
| 77077 |
|
144 |
135 |
$2K |
| 86147 |
|
67 |
48 |
$2K |
| 51741 |
|
303 |
290 |
$2K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
1,376 |
1,242 |
$2K |
| 0390 |
|
443 |
163 |
$2K |
| 76857 |
|
123 |
122 |
$2K |
| 85097 |
|
66 |
64 |
$2K |
| 83001 |
|
165 |
146 |
$2K |
| C1781 |
Mesh (implantable) |
12 |
12 |
$2K |
| 84432 |
|
152 |
147 |
$2K |
| 51728 |
|
15 |
15 |
$2K |
| 82024 |
|
44 |
39 |
$2K |
| 84520 |
|
1,350 |
1,245 |
$2K |
| J9394 |
Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg |
33 |
25 |
$2K |
| 95970 |
|
88 |
88 |
$2K |
| 86300 |
|
116 |
98 |
$2K |
| J9370 |
Vincristine sulfate, 1 mg |
316 |
178 |
$2K |
| J7121 |
5% dextrose in lactated ringers infusion, up to 1000 cc |
478 |
339 |
$2K |
| 92060 |
|
260 |
246 |
$2K |
| 86256 |
|
180 |
167 |
$2K |
| 90935 |
Hemodialysis procedure with single evaluation by a physician |
17 |
13 |
$2K |
| J9171 |
Injection, docetaxel, 1 mg |
154 |
75 |
$2K |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
1,162 |
901 |
$2K |
| 36573 |
|
15 |
12 |
$2K |
| 86769 |
|
132 |
83 |
$2K |
| 82435 |
|
1,324 |
1,220 |
$2K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
854 |
613 |
$2K |
| 96150 |
|
55 |
52 |
$2K |
| 80164 |
|
217 |
181 |
$2K |
| 12002 |
|
173 |
170 |
$2K |
| 84300 |
|
599 |
535 |
$2K |
| J7070 |
Infusion, d5w, 1000 cc |
324 |
222 |
$2K |
| 80158 |
|
117 |
37 |
$2K |
| 88311 |
|
483 |
450 |
$2K |
| 74246 |
|
24 |
24 |
$2K |
| 95957 |
|
18 |
18 |
$2K |
| 87106 |
|
280 |
239 |
$2K |
| 85045 |
|
671 |
543 |
$2K |
| 86870 |
|
14 |
13 |
$1K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
8,613 |
7,602 |
$1K |
| 86376 |
|
129 |
127 |
$1K |
| 72070 |
|
139 |
139 |
$1K |
| G0257 |
Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility |
33 |
26 |
$1K |
| 88262 |
|
43 |
42 |
$1K |
| 89051 |
|
1,794 |
1,430 |
$1K |
| 43762 |
|
38 |
37 |
$1K |
| 90750 |
|
69 |
60 |
$1K |
| 85576 |
|
197 |
101 |
$1K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
1,796 |
1,526 |
$1K |
| S0077 |
Injection, clindamycin phosphate, 300 mg |
321 |
251 |
$1K |
| 0071A |
|
34 |
34 |
$1K |
| 86592 |
|
396 |
374 |
$1K |
| J1940 |
Injection, furosemide, up to 20 mg |
1,302 |
997 |
$1K |
| 97003 |
|
157 |
90 |
$1K |
| 12001 |
|
146 |
144 |
$1K |
| 99497 |
|
61 |
61 |
$1K |
| 11900 |
|
123 |
118 |
$1K |
| 86039 |
|
147 |
144 |
$1K |
| A4649 |
Surgical supply; miscellaneous |
29 |
27 |
$1K |
| 11102 |
|
90 |
89 |
$1K |
| 11100 |
|
26 |
25 |
$1K |
| 88333 |
|
67 |
64 |
$1K |
| 92611 |
|
39 |
39 |
$1K |
| 77012 |
|
30 |
28 |
$1K |
| 10005 |
|
14 |
12 |
$1K |
| 70487 |
|
12 |
12 |
$1K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
384 |
355 |
$1K |
| 0072A |
|
28 |
28 |
$1K |
| 96377 |
|
206 |
154 |
$1K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
1,446 |
1,285 |
$1K |
| 87493 |
|
54 |
51 |
$1K |
| 97535 |
Self-care/home management training, each 15 minutes |
527 |
472 |
$1K |
| 86593 |
|
287 |
274 |
$1K |
| 87533 |
|
27 |
13 |
$1K |
| J1580 |
Injection, garamycin, gentamicin, up to 80 mg |
555 |
429 |
$1K |
| 84703 |
|
317 |
294 |
$983.05 |
| 99070 |
|
336 |
192 |
$968.58 |
| 36590 |
|
12 |
12 |
$967.05 |
| J0689 |
Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg |
122 |
95 |
$951.08 |
| 86644 |
|
78 |
54 |
$922.97 |
| 80177 |
|
238 |
195 |
$914.05 |
| C1773 |
Retrieval device, insertable (used to retrieve fractured medical devices) |
98 |
98 |
$893.68 |
| J3535 |
Drug administered through a metered dose inhaler |
285 |
227 |
$849.49 |
| 92612 |
|
12 |
12 |
$803.67 |
| 84157 |
|
493 |
384 |
$802.01 |
| 88334 |
|
49 |
48 |
$776.58 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
564 |
410 |
$745.11 |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
303 |
197 |
$707.59 |
| 0346T |
|
26 |
25 |
$707.41 |
| 86146 |
|
52 |
25 |
$706.03 |
| 95816 |
|
24 |
24 |
$702.92 |
| L0140 |
Cervical, semi-rigid, adjustable (plastic collar) |
13 |
12 |
$699.85 |
| J1250 |
Injection, dobutamine hydrochloride, per 250 mg |
227 |
219 |
$689.92 |
| 51784 |
|
27 |
27 |
$677.99 |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
24 |
24 |
$673.23 |
| 94727 |
|
64 |
61 |
$672.77 |
| 83002 |
|
66 |
62 |
$664.71 |
| J1630 |
Injection, haloperidol, up to 5 mg |
1,075 |
887 |
$661.90 |
| 88331 |
|
37 |
37 |
$659.44 |
| J0744 |
Injection, ciprofloxacin for intravenous infusion, 200 mg |
270 |
235 |
$652.14 |
| 51797 |
|
27 |
27 |
$632.43 |
| 93246 |
|
298 |
295 |
$631.63 |
| 99201 |
|
12 |
12 |
$620.34 |
| 94799 |
|
167 |
153 |
$620.00 |
| 90656 |
|
40 |
40 |
$609.44 |
| 71010 |
|
57 |
56 |
$595.60 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
721 |
667 |
$588.32 |
| 86787 |
|
46 |
28 |
$587.76 |
| A6258 |
Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing |
873 |
806 |
$585.87 |
| 12011 |
|
41 |
40 |
$585.27 |
| S0164 |
Injection, pantoprazole sodium, 40 mg |
174 |
117 |
$547.24 |
| 82945 |
|
298 |
234 |
$536.44 |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
5,280 |
3,689 |
$531.70 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
455 |
294 |
$502.87 |
| 96549 |
|
214 |
131 |
$492.05 |
| 86922 |
|
16 |
13 |
$483.65 |
| 29125 |
|
80 |
75 |
$481.43 |
| 83935 |
|
160 |
149 |
$474.63 |
| J1610 |
Injection, glucagon hydrochloride, per 1 mg |
13 |
13 |
$456.29 |
| 92610 |
|
30 |
28 |
$435.68 |
| 31624 |
|
13 |
12 |
$435.30 |
| 77387 |
|
227 |
50 |
$432.76 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
1,168 |
879 |
$427.26 |
| 84681 |
|
31 |
30 |
$425.32 |
| 76001 |
|
28 |
24 |
$421.50 |
| J0688 |
Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg |
161 |
153 |
$416.40 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
1,555 |
572 |
$413.13 |
| 92225 |
|
29 |
26 |
$374.73 |
| 99221 |
|
14 |
12 |
$371.36 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
563 |
492 |
$370.97 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
282 |
260 |
$367.03 |
| 93270 |
|
12 |
12 |
$364.00 |
| 85613 |
|
52 |
49 |
$351.66 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
1,157 |
602 |
$342.76 |
| 73522 |
|
26 |
25 |
$339.08 |
| 92522 |
|
28 |
24 |
$324.19 |
| 11721 |
|
909 |
885 |
$316.73 |
| 17110 |
|
119 |
115 |
$315.35 |
| C1758 |
Catheter, ureteral |
65 |
49 |
$309.81 |
| 93978 |
|
13 |
12 |
$293.01 |
| 36589 |
|
12 |
12 |
$288.54 |
| 77332 |
|
17 |
14 |
$280.70 |
| 95983 |
|
15 |
14 |
$261.66 |
| J3371 |
Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg |
164 |
127 |
$251.98 |
| 84480 |
|
26 |
24 |
$242.94 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
34 |
19 |
$241.87 |
| 86430 |
|
73 |
72 |
$232.57 |
| 95836 |
|
27 |
26 |
$231.14 |
| 81015 |
|
178 |
165 |
$226.84 |
| 86317 |
|
41 |
37 |
$226.49 |
| 83930 |
|
57 |
53 |
$218.69 |
| 87400 |
|
94 |
93 |
$216.51 |
| 84425 |
|
40 |
39 |
$206.22 |
| 84155 |
|
137 |
132 |
$205.30 |
| 97163 |
|
25 |
24 |
$180.06 |
| 92201 |
|
13 |
12 |
$180.04 |
| 82787 |
|
27 |
13 |
$176.67 |
| 86753 |
|
16 |
12 |
$174.28 |
| 71101 |
|
12 |
12 |
$173.70 |
| 83655 |
|
30 |
30 |
$166.60 |
| 84481 |
|
14 |
14 |
$163.42 |
| 82247 |
|
33 |
24 |
$156.39 |
| 96127 |
|
12 |
12 |
$154.86 |
| 83010 |
|
15 |
12 |
$140.95 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
35 |
25 |
$132.51 |
| 85014 |
|
111 |
101 |
$132.43 |
| 85347 |
|
61 |
38 |
$125.51 |
| 86308 |
|
28 |
28 |
$118.12 |
| G0127 |
Trimming of dystrophic nails, any number |
13 |
13 |
$114.66 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
13 |
13 |
$110.25 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
52 |
39 |
$105.20 |
| 87045 |
|
13 |
12 |
$103.40 |
| 76514 |
|
110 |
110 |
$103.26 |
| 83550 |
|
28 |
27 |
$102.07 |
| L4386 |
Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
13 |
13 |
$99.66 |
| 20550 |
|
14 |
12 |
$96.52 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
51 |
49 |
$95.96 |
| S0028 |
Injection, famotidine, 20 mg |
5,239 |
3,061 |
$94.68 |
| 82962 |
|
129 |
104 |
$94.38 |
| A6257 |
Transparent film, sterile, 16 sq. in. or less, each dressing |
1,107 |
939 |
$88.76 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
12 |
12 |
$82.66 |
| 99001 |
|
247 |
225 |
$80.00 |
| 83006 |
|
14 |
13 |
$78.51 |
| 82042 |
|
59 |
39 |
$76.24 |
| J0692 |
Injection, cefepime hydrochloride, 500 mg |
18 |
12 |
$70.67 |
| J2590 |
Injection, oxytocin, up to 10 units |
12 |
12 |
$67.86 |
| 86580 |
|
43 |
41 |
$67.82 |
| 84460 |
|
13 |
12 |
$64.74 |
| 81479 |
Unlisted molecular pathology procedure |
29 |
27 |
$62.87 |
| 51736 |
|
15 |
15 |
$62.58 |
| J1950 |
Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
12 |
12 |
$61.52 |
| 87046 |
|
26 |
12 |
$60.91 |
| 82595 |
|
14 |
13 |
$60.29 |
| 84540 |
|
27 |
25 |
$48.61 |
| J1953 |
Injection, levetiracetam, 10 mg |
23 |
12 |
$48.23 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
304 |
274 |
$47.80 |
| J1920 |
Injection, labetalol hydrochloride, 5 mg |
17 |
15 |
$42.50 |
| 51701 |
|
13 |
13 |
$42.00 |
| L3908 |
Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf |
12 |
12 |
$40.74 |
| 69209 |
|
17 |
16 |
$37.61 |
| 0272 |
|
891 |
545 |
$37.59 |
| A6457 |
Tubular dressing with or without elastic, any width, per linear yard |
14 |
13 |
$35.86 |
| A6213 |
Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing |
12 |
12 |
$33.96 |
| J1643 |
Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units |
46 |
46 |
$32.68 |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
399 |
158 |
$25.84 |
| 82465 |
|
14 |
13 |
$25.52 |
| S5010 |
5% dextrose and 0.45% normal saline, 1000 ml |
426 |
314 |
$24.50 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
17 |
14 |
$24.21 |
| 81050 |
|
14 |
13 |
$23.64 |
| 83986 |
|
15 |
13 |
$19.57 |
| A4217 |
Sterile water/saline, 500 ml |
28 |
27 |
$15.98 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
32 |
29 |
$15.88 |
| J2004 |
Injection, lidocaine hcl with epinephrine, 1 mg |
23 |
16 |
$10.88 |
| A9150 |
Non-prescription drugs |
174 |
126 |
$9.94 |
| 72050 |
|
14 |
14 |
$9.29 |
| A6222 |
Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing |
146 |
124 |
$7.88 |
| 11000 |
|
15 |
13 |
$6.00 |
| A9270 |
Non-covered item or service |
829 |
453 |
$4.42 |
| 20611 |
|
12 |
12 |
$3.38 |
| J2730 |
Injection, pralidoxime chloride, up to 1 gm |
12 |
12 |
$2.88 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
628 |
580 |
$1.59 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
571 |
530 |
$1.55 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
139 |
122 |
$0.69 |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
134 |
117 |
$0.68 |
| Q0164 |
Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
67 |
59 |
$0.59 |
| G8996 |
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals |
135 |
116 |
$0.24 |
| G8997 |
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
144 |
123 |
$0.24 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
227 |
209 |
$0.08 |
| G8989 |
Self care functional limitation, discharge status, at discharge from therapy or to end reporting |
16 |
13 |
$0.05 |
| 0519 |
|
221 |
179 |
$0.00 |
| 0611 |
|
89 |
87 |
$0.00 |
| 0305 |
|
103 |
87 |
$0.00 |
| 90480 |
|
13 |
13 |
$0.00 |
| 0440 |
|
22 |
15 |
$0.00 |
| 0610 |
|
51 |
43 |
$0.00 |
| 0335 |
|
687 |
228 |
$0.00 |
| 0310 |
|
406 |
164 |
$0.00 |
| 0341 |
|
21 |
20 |
$0.00 |
| G8998 |
Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting |
49 |
38 |
$0.00 |
| 0780 |
|
1,576 |
1,418 |
$0.00 |
| 3044F |
|
51 |
51 |
$0.00 |
| 0636 |
|
4,468 |
1,474 |
$0.00 |
| 0482 |
|
17 |
17 |
$0.00 |
| 0409 |
|
14 |
13 |
$0.00 |
| 0612 |
Calcium glucon (wg critical) |
23 |
13 |
$0.00 |
| 0280 |
|
66 |
47 |
$0.00 |
| S0030 |
Injection, metronidazole, 500 mg |
162 |
94 |
$0.00 |
| 0349 |
|
37 |
32 |
$0.00 |
| 0276 |
|
17 |
14 |
$0.00 |
| 0481 |
|
37 |
13 |
$0.00 |
| 99072 |
|
282 |
149 |
$0.00 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
91 |
87 |
$0.00 |
| 0489 |
|
95 |
62 |
$0.00 |
| 0260 |
|
560 |
237 |
$0.00 |
| 0278 |
|
140 |
104 |
$0.00 |
| 0483 |
|
62 |
50 |
$0.00 |
| 0311 |
|
41 |
40 |
$0.00 |
| 0361 |
|
49 |
28 |
$0.00 |
| 0920 |
|
406 |
251 |
$0.00 |
| 0921 |
|
22 |
18 |
$0.00 |
| 0750 |
|
107 |
76 |
$0.00 |
| 0333 |
|
209 |
23 |
$0.00 |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
73 |
70 |
$0.00 |
| 0343 |
|
27 |
27 |
$0.00 |
| 0940 |
|
94 |
61 |
$0.00 |
| 0460 |
|
60 |
36 |
$0.00 |
| 0274 |
|
21 |
19 |
$0.00 |
| 0623 |
|
37 |
25 |
$0.00 |
| 91322 |
|
13 |
13 |
$0.00 |